ArticleOrganic & biomolecular chemistry2025
Semisynthesis of bersavine and berbamine derivatives that target the CaMKIIγ:cMyc axis for lymphoma therapy.
Berkley Lujan, Mingfeng Zhang, Yujie Cao, Arnav Kacker, Lina Mai, Shunquan Wu, Taylor Alexander, Wendong Huang, Kevin G M Kou
Abstract read
In one paragraphArticle in Organic & biomolecular chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Berkley LujanDepartment of Chemistry, University of California, Riverside, California 92507, USA. kevin.kou@ucr.edu.
Mingfeng ZhangDepartment of Diabetes Complications & Metabolism Research, City of Hope National Medical Center, Duarte, California 91010, USA.
Yujie CaoDepartment of Chemistry, University of California, Riverside, California 92507, USA. kevin.kou@ucr.edu.
Arnav KackerDepartment of Chemistry, University of California, Riverside, California 92507, USA. kevin.kou@ucr.edu.
Lina MaiDepartment of Chemistry, University of California, Riverside, California 92507, USA. kevin.kou@ucr.edu.
Shunquan WuDepartment of Diabetes Complications & Metabolism Research, City of Hope National Medical Center, Duarte, California 91010, USA.
Taylor AlexanderDepartment of Chemistry, University of California, Riverside, California 92507, USA. kevin.kou@ucr.edu.
Wendong HuangDepartment of Diabetes Complications & Metabolism Research, City of Hope National Medical Center, Duarte, California 91010, USA.
Kevin G M KouDepartment of Chemistry, University of California, Riverside, California 92507, USA. kevin.kou@ucr.edu.ORCID 0000-0002-4676-8846 Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3MBile acids and metabolic surgeryR01DK124627 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI HUANG, WENDONG · 2020 to 2024
$2.0MTargeting bile acid composition to treat metabolic diseasesR01DK138665 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WENDONG HUANG, John Jefferson Perry · 2024 to 2026
$1.9MNCI NIH HHS P30 CA033572NIDDK NIH HHS R01 DK124627NIDDK NIH HHS R01 DK138665
6 · The paper itselfAbstract
Berbamine, a bisbenzylisoquinoline alkaloid (bisBIA), is a promising lead for developing novel therapeutics to treat aggressive cancers such as lymphoma, by targeting the CaMKIIγ:cMyc axis. Herein, we report an aza-Friedel-Crafts method for
Indexed as
Antineoplastic AgentsBenzylisoquinolinesCalcium-Calmodulin-Dependent Protein Kinase Type 2LymphomaProtein Kinase InhibitorsProto-Oncogene Proteins c-mycCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBenzylisoquinolinesberbamineCalcium-Calmodulin-Dependent Protein Kinase Type 2Protein Kinase InhibitorsProto-Oncogene Proteins c-myc
Identifiers
PMID40202443
PMCPMC12058378
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390